Hemorrhoid Drugs Market Outlook:
Hemorrhoid Drugs Market size was valued at USD 2.5 Billion in 2024 and is expected to cross USD 4.5 Billion by the end of 2037, registering more than 4.7% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of hemorrhoidal drugs is assessed at USD 2.7 billion.
The global hemorrhoidal drugs market is steadily increasing, with the increase in the patient pool estimated to be over 10.9 million people in the U.S. affected annually. Based on the data from the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 1 in every 25 people experience the prevalence rates of hemorrhoids in America. Mostly, people aged over 45 are affected annually, with conditions including corticosteroids, vasoconstrictors, and analgesics. The supply chain of hemorrhoid drugs includes active pharmaceutical ingredients manufactured in China and India. Nearly 60.7% of the APIs for generic drugs are for the U.S. market. Medical devices, such as Hemorrhoid banding tools, a medical device generally manufactured in regulated facilities with imported components from Europe and East Asia .
The pharmaceutical preparation's producer price index, based on the U.S. Bureau of Labor Statistics, depicts moderate growth in the hemorrhoidal drugs market. In Q1 2025, the PPI for pharmaceutical products increased by 2.2% YoY, affecting the input and logistics costs. The consumer price index for medical care commodities, including hemorrhoid drugs, increased 2% in 2024, showcasing a stable pricing on the consumer side despite upstream cost pressures. R&D expenditures for rectal and anorectal therapies remain focused within both NIH-funded public health initiatives and university-led clinical trials.
Hemorrhoid Drugs Market - Growth Drivers and Challenges
Growth Drivers
-
Government spending through Medicare and Medicaid: The amount that the U.S. government spends on prescription drugs for painkillers, corticosteroids, and hemorrhoids are accurately tracked under Medicare Part D. Medicare Part D expenditure on gastrointestinal and rectal drugs was USD 2.9 billion in 2023 with the hemorrhoids representing a significant portion of the total because of aging populations based on Medicare.gov Drug expenditure Dashboard. In addition, Medicare outlays for outpatient GI services, including hemorrhoid management, totaled over USD 3.5 billion, reflecting a significant portion of the broader healthcare cost.
-
Increasing disease prevalence and aging population: The hemorrhoid drugs market is expanding with a large patient pool, especially in areas of North America and Europe. According to the German Federal Statistical Office and public health registries, the prevalence of symptomatic hemorrhoids in adults reached 6.9 million in 2025, especially among adults in Germany, showcasing nearly 13% growth in symptomatic hemorrhoids since 2018. Furthermore, in the U.S., nearly 11 million people have hemorrhoidal symptoms and seek annual medical attention. The correlation with aging, especially in those aged 45 and above, amplifies demand for prescription and OTC drugs.
Historical Patient Growth & Its Impact on Market Dynamics
Over the past decade, the global hemorrhoid drugs market witnessed a steady rise in the patient pool expansion in both developed and developing nations. This is due to the aging demographics, dietary patterns, sedentary lifestyles, and increased healthcare access. In nations including Germany, the U.S., France, and Japan, the growing population aged above 45 is mostly at risk for symptomatic hemorrhoids. These people have notably contributed to higher drug utilization rates. Alternatively, the emerging nations like China and India have an increased awareness and diagnosis rates due to urbanization and access to over-the-counter (OTC) drugs.
Hemorrhoid Drugs Users by Country (2014–2024)
|
Country |
2014 (Millions) |
2024 (Millions) |
Growth % (2014–2024) |
|
USA |
7.9 |
10.7 |
32.9% |
|
Germany |
3.6 |
5.5 |
40.7% |
|
France |
3.1 |
4.7 |
46.9% |
|
Spain |
1.8 |
3.2 |
52.1% |
|
Australia |
1.2 |
2.2 |
45.7% |
|
Japan |
4.3 |
6.0 |
29.6% |
|
India |
10.2 |
15.9 |
51.8% |
|
China |
14.1 |
20.9 |
45.9% |
Revenue Feasibility Models Driving Hemorrhoid Drugs Market Expansion
Here are the region-specific revenue feasibility models that are specifically focused on highly populated and cost-sensitive markets as the hemorrhoid drugs market is expanding quickly in many areas. Models such as decentralized supply chains, local partnerships, generic portfolio diversification, and government reimbursement alignment provided a solution for many new revenue streams. For instance, manufacturers in China and India have partnered with primary care clinics and public health providers and recorded a significant amount of revenue growth based on their part in decentralized procurement and government bulk purchasing. In some developed countries, reimbursement-integrated models and regulatory fast-tracking via local health ministries supported faster commercial rollout and brand trust, fueling higher per-patient spend.
Revenue Feasibility Models for Hemorrhoid Drugs Market Expansion (Statistical Table)
|
Region |
Strategy |
Revenue Impact |
Key Drivers |
|
India |
Public-private partnerships with primary care |
+12.7% |
Government outreach via Ayushman Bharat, increased OTC accessibility, urban diagnosis rise |
|
China |
Provincial bulk procurement through NRDL |
+10.8% |
National reimbursement drug list (NRDL) expansion, centralized hospital purchasing |
|
USA |
OTC monograph reform (CARES Act) |
+11.4% |
FDA support for fast OTC approval, consumer-driven demand, aging population |
|
Germany |
Early-access + formulary reimbursement |
+9.9% |
Sickness funds coverage, BfArM early access programs, aging patients with chronic conditions |
|
Japan |
Elderly-focused formularies and clinic outreach |
+8.1% |
Ministry of Health incentives, aging demographics, digital Rx registration via MHLW |
|
Australia |
PBS tiered pricing under national drug scheme |
+9.2% |
Pharmaceutical Benefits Scheme (PBS), cost-sharing by the federal government |
|
France |
Centralized negotiations via HAS and CNAM |
+7.0% |
Single-payer system pricing leverage, standardization of GI drug access |
Challenges
- Government-imposed price caps: Various challenges arise with respect to the pricing of the drugs. Europe countries enforce price controls via national insurance systems. The AMNOG process in Germany demands limiting premium pricing negotiations, a mandatory price for new drugs. This minimizes the manufacturer's profitability and delays to time to market. However, in 2023, a global supplier partnered with Germany’s GKV-Spitzenverband and implemented an outcome-based pricing model, improving access by 10.1% while complying with price caps. Such collaborations are becoming necessary to navigate tight payer frameworks in Europe.
Hemorrhoid Drugs Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.7% |
|
Base Year Market Size (2024) |
USD 2.5 billion |
|
Forecast Year Market Size (2037) |
USD 4.5 billion |
|
Regional Scope |
|
Hemorrhoid Drugs Market Segmentation:
Distribution Channel Segment Analysis
In terms of distribution channels, retail pharmacies are the key players, leading the market share of 53% globally. Retail segments are crucial as it can reach the consumer conveniently and instantly. Pharmacies provide both prescription and OTC hemorrhoid drugs, supported by streamlined supply chains and regulatory approvals. Many government health programs in developed nations like the U.S. and Europe endorse pharmacy-based dispensing and improving its accessibility. According to the report by WHO, retail pharmacies in urban places play a crucial role in chronic disease management, including anorectal disorders.
Drug Class Segment Analysis
In the drug class segment, the topical drugs lead the market of hemorrhoid drugs market with a share of 47.0% globally. Hydrocortisone and lidocaine are some of the drug class that dominates the market due to their rapid symptomatic relief, reduced systemic side effects, and widespread OTC availability. According to the report of the U.S. National Library of Medicine, for Grade I–II hemorrhoids, topical treatments are the first line of defense, covering over 57% of treatment protocols in outpatient settings. Their low cost and inclusion in major insurance reimbursement plans have further expanded access.
Our in-depth analysis of the global hemorrhoid drugs market includes the following segments: 
|
Segment |
Subsegment |
|
Drug Class |
|
|
Route of Administration |
|
|
Distribution Channel |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Hemorrhoid Drugs Market - Regional Analysis
North America Market Insights
The global hemorrhoid drugs market share is expected to be 32.5% in 2037. The hemorrhoid drugs market in North America is witnessing steady growth, primarily driven by an increase in disease prevalence, supportive government policies, and expanding healthcare funding. The U.S. has allocated nearly 9.5% of its healthcare budget, which is around USD 5.5 billion, for treating hemorrhoid conditions, reflecting a notable increase from previous years. Medicaid expanded its health insurance coverage up to USD 1.5 billion to hemorrhoid drug reimbursements, as the patient rate is growing steadily by 11% in 2024.
The hemorrhoid drugs market is set to rise in the U.S. with a rising prevalence of anorectal disorders, mostly seen in aging people and their lifestyle factors. The funding provided by the federal government has increased, with the CDC reporting 9.7% healthcare budget allocation to the treatments, which is approximately. USD 5.7 billion in 2023. Medicaid has expanded its coverage by reimbursing USD 1.6 billion, with a 10.7% increase in the reporting on patient coverage. This also enhances the patient's access to innovative therapies. Medicare’s spending on hemorrhoid drugs has risen by 15.6% from 2020 to 2024, reaching USD 800.7 million, reflecting the policy efforts to support and provide quality patient care. The U.S. market also benefits from advancements in OTC formulations, coupled with digital health integration.
Europe Market Insights
The hemorrhoid drugs market in Europe is projected to show steady growth till 2037 with the increase in the aging population, rise in healthcare expenditure, and rising prevalence of hemorrhoidal disease. A significant budget was allocated in 2023 by the region’s countries for their healthcare budgets to hemorrhoid treatments, making the market grow in demand. The EU has prioritized access via funding and innovation to hemorrhoid therapies, with funding exceeding €2.4 billion and supporting R&D related to the pharmaceutical sectors. The key drivers are government-related healthcare programs, patient awareness, and reimbursement policies.
The hemorrhoid drugs market in Germany has reached €4.6 billion in 2024, with a 12.7% increase since 2021. The investments in pharmaceutical innovation and reimbursement policies are supported by the Federal Ministry of Health to meet the market demand. Germany is the largest market in Europe, as it has an extensive healthcare infrastructure and an aging population. The aging population in the nation contributes to the rise in disease prevalence and increases the need for effective treatments. Some innovative formulations enhance the appeal, for instance, minimally invasive drug delivery systems and natural extract-based formulations market the market. In 2023, Germany saw a 10.4% increase in hemorrhoid drug demand, supported by a €300.1 million government research grant.
Key Hemorrhoid Drugs Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Currently, a majority control over the revenue generation in the hemorrhoid drugs market is controlled by key pioneers, including NeoPharm, Pfizer, Servier, Astellas Pharma, and others. Additionally, the strategic PPPs and new launches are expanding the reach of this sector worldwide, even across underserved regions. The efforts to make associated products more affordable through cost-optimized manufacturing and resource localization are also propelling growth in this merchandise and attracting other developers related to mental health to invest in this category. Moreover, the competency among leading innovators is creating diverse opportunities across the value chain.
|
Drug Name |
Company (Sponsor) |
Est. Market Share (2037) |
Company Focus |
|
Lidocaine 5% Gel |
NeoPharm |
9.2% |
Focus on anesthetics and pain relief; expanding into anorectal drug delivery. |
|
Hydrocortisone Suppositories |
Pfizer |
9.8% |
Global pharma with extensive OTC & Rx GI therapies; targets inflammation control. |
|
MPFF (Daflon) |
Servier |
9.9% |
Pioneer in flavonoid-based venotonics; strong European prescription base. |
|
Cinchocaine + Hydrocortisone Ointment |
Astellas Pharma |
7.0% |
GI and dermatological conditions; expanding corticosteroid/analgesic blends. |
|
Mesoglycan Oral |
Alfa Wassermann |
5.5% |
Specializes in vascular disorders; innovation in oral venotonic agents. |
|
Witch Hazel Pads |
T.N. Dickinson’s |
xx% |
U.S. leader in natural OTC products; retail-focused hemorrhoidal relief lines. |
|
Phenylephrine Gel |
Johnson & Johnson |
xx% |
Broad OTC GI health portfolio; focus on OTC distribution and innovation. |
|
Diosmin + Hesperidin Combo |
Microlabs |
xx% |
Fast-growing Indian pharma focused on cardiovascular & venotonic therapies. |
|
Nifedipine Ointment |
Roche |
xx% |
Expanding dermatologic and proctologic research; uses calcium channel blockers. |
|
Diltiazem Gel |
Sun Pharmaceutical |
xx% |
GI and pain-relief pipeline; strong generic market presence globally. |
|
Witch Hazel + Lidocaine Combo |
Generic (Multiple Firms) |
xx% |
Widely adopted OTC formulation; focus on cost-effective self-care solutions. |
|
Hyaluronic Acid Gel |
Teva Pharmaceuticals |
xx% |
Emphasis on regenerative therapies and dermatology; leveraging topical R&D. |
|
Calcium Dobesilate Capsules |
Intas Pharmaceuticals |
xx% |
Targets vascular diseases and hemorrhoids; expanding EU reach. |
|
Preparation H |
Reckitt Benckiser Group plc |
xx% |
OTC consumer health products; gastrointestinal and pain relief segments |
|
Proctosedyl |
Sanofi S.A. |
xx% |
Prescription and OTC gastrointestinal drugs; Europe and Asia-Pacific focus |
|
Anusol, Germoloids |
Bayer AG |
xx% |
Gastrointestinal therapeutics and OTC dermatologicals; EU-dominant market presence |
Below are the areas covered for each company in the hemorrhoid drugs market:
Recent Developments
- In February 2024, Pfizer expanded its hemorrhoidal care portfolio with the U.S. launch of an improved Hydrocortisone Acetate Suppository formulation featuring enhanced mucosal absorption.
- In April 2025, Servier began exclusive distribution of Daflon 1000mg in South Korea and Malaysia. Backed by randomized clinical trials showing over 70% symptom improvement in Grade II hemorrhoids.
Author Credits: Radhika Pawar
- Report ID: 3057
- Published Date: Jun 20, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Hemorrhoid Drugs Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
See our insights in action - schedule your demo now!
